Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir vs Lopinavir/Ritonavir in ARV Naive HIV Patients
NCT00144105Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2004
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of tipranavir in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Proportion of treatment responders with viral load < 50 copies/mL at 48 weeks. Started Feb 2004; status: terminated.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00144105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144105.